Trial Search Results

An Extension Study for Subjects Who Are Deriving Benefit With Idelalisib (GS-1101; CAL-101) Following Completion of a Prior Idelalisib Study

This is a long-term safety extension study of IDELA (idelalisib) in subjects with hematologic malignancies who complete other IDELA studies. Subjects will be followed according to the standard of care as appropriate for their type of cancer, and will be treated at the dosage level received upon completion of their prior IDELA study. Subjects will be withdrawn from the study if they develop progressive disease, unacceptable toxicity related to IDELA, or if they no longer derive clinical benefit in the opinion of the investigator

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Gilead Sciences


  • Drug: Idelalisib


Phase 1/Phase 2


Key Inclusion Criteria:

   - Patients with hematologic malignancies completing a prior idelalisib study with a
   clinical benefit are eligible

   - Women of childbearing potential must have a negative pregnancy test to be eligible

   - Male patients, and female patients of childbearing potential, must agree to use
   method(s) of contraception specified in the protocol

Key Exclusion Criteria:

   - Patients who are unwilling or unable to comply with the protocol are not eligible

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Not Recruiting